Medical Doctor Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Nathaniel Berg

Vascular & Interventional Radiology Tamuning, GU Medical Doctor

NPI 1265646806 CMS profile 371476

633 Governor Carlos Camacho Road, Suite 210, Tamuning, GU 96913

Open in the dashboard

General payments

$942

16 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$742,805

1 holding reported · through program year 2023

Through program year 2023, Nathaniel Berg of Tamuning, GU is reported in the CMS Open Payments database as having received $942 across 16 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $742,805 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 28th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $928 15
2021 General $14 1
2022 Ownership $742,805 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nathaniel Berg
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Nathaniel Berg were reported at $0. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Nathaniel Berg Vascular & Interventional Radiology median Middle half National median
2019 $0 $422 $125–$1,555 $163
2020 $0 $200 $68–$652 $114
2021 $14 $280 $99–$866 $132
2022 $0 $433 $137–$1,497 $149
2023 $928 $506 $152–$2,019 $160
2024 $0 $556 $175–$1,930 $164
2025 $0 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Abbott Laboratories $928 15 payments
  2. AngioDynamics, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $942 16 payments
Products named General payments · program years 2021–2023
  1. PROCLAIM Neuromodulation $543 7 payments
  2. PROCLAIM Neuromodulation $331 6 payments
  3. PROCLAIM Neuromodulation $32 1 payment
  4. ETERNA $22 1 payment
  5. Auryon Laser System 100-120 Vac $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 225 billing codes

Paid by Medicare

$521,015

Of which drugs: $3,595

Medicare patients

2,621

Average age 72

Services billed

31,719

1,337 women, 1,284 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 63%
Ischemic heart disease 46%
Chronic kidney disease 43%
Heart failure 40%
Arthritis 33%
COPD 24%
Atrial fibrillation 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 191 20,462 $1,809
Injection, gadoterate meglumine, 0.1 ml A9575 Office 18 2,660 $223
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 14 16 $64
Injection, fentanyl citrate, 0.1 mg J3010 Office 79 86 $58
Injection, heparin sodium, per 1000 units J1644 Office 48 209 $39
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 29 122 $29
Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 Office 22 27 $24
Injection, midazolam hydrochloride, per 1 mg J2250 Office 72 140 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

16 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Guam

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record